and CEO. is technology Sonia. neurostim applied with health I'm technology NeuroMetrix proprietary on company you, chronic and by diabetes. joined disorders President pain, Dr. sleep in call a Thank our the Shai Gozani,
neuropathy. DPNCheck, level quarter pain primary test for are managing Our products of commercial peripheral chronic was an over-the-counter for the a second point-of-care activity device in There wearable a and XXXX. Quell, diabetic of high
interest. We maintained in Sciences a the monetizing of over revenue with the Life Quell of GSK Advisors well. In on previous and to QX, technology a for DPNCheck quarters a performing the Quell was continued trends earnings possibility the Bay topic last organize Development explore process calls. banker level. version investment we business, DPNCheck to we've several soliciting of Back mentioned high support Revenue took decline retained steps the at formal an
has recent margins a It line as revenue direct XX% on interest We This it a of with opportunity. to late is of bolt-on range highest generated last been in in an years. million in a nicely, product have XX% exceeding rate goal $X.X basis. EBITDA Our attractive growing cost growth in generates see the by year and sense QX. good
and operating workforce recent And improve areas conserve lower operating a CapEx our We force. quarter. with second in were by This lower Headcount combined should year, the costs was with initiated a XX%. in alignment Severance $XXX,XXX. over this were business addressed. step, restructuring activities, costs, through cash. in QX earlier reduced has in the reduction Three
the office labs. costs our will closing and of engineering with corporate lowered be Facility
these During manufacturing our QX for we will are offer at space. into $XXX,XXX. and the then Relocation local relocate vacated functions estimated facility sub-let costs
quarters We for excess the a X.X Quell $X.X business valued has with recorded value. $X.X which above a that lines supply beyond in The not electronics, typical is quarter stock was in was of realizable the million Quell inventory. sales us parts left X.X over extending -- in second excess million. a recent net total volume charge With restructuring year, reduction charge booked
issues advertising. sought resolve we Also, as the Federal that occasions several on met we Trade center to on Quell Commission with
the financials Quell of included million $X.X Turning $X.X this million that from year. $X.X was $X.X to morning's last release, million last was down from in million, QX of press were in down year. of QX total $XXX,XXX revenue revenue XX%
in measured acquisition year-on-year. XX% objective in acquiring on customers. Quell by change new Digital promotion. did discontinued as improve reduced Direct spending over or costs. quarters, advertising to million favor TV of promotion The profitability digital past of improved advertising was spending the was customer versus the yield terms was $X.X in the several efficiency of QX of
quarter or volume in expand ad drive to However, efficiency. the sacrificing to without spending we meaningfully were grow unable increased spending
continuing are our approach. refine to digital We
while both QX did last of the a strong last Sales with even $X.X was make year roughly QX Mexico DPNCheck year. QX Medicare was contribution. Japan particularly business revenue in million prior strong our revenue were up in XX% revenue U.S. not year, Advantage, flat of year-on-year. and with
in disarray Mexico in distributor government fiscal markets following government last Mexico year. economic with and change local Our sector is the in dealing the
from for over and to Legacy product of in prior year. was products These are lines is time. the flow older expected down sales cash decline $XXX,XXX volume diagnostic $XXX,XXX managed revenue of these
margin a of Our negative quarter -- the a result impairment inventory of profit million. the as was $X.X gross $XXX,XXX in charge gross
that of million of level Excluding of represented rate rate a XX% the profit margin impairment approximately last charge gross year. with QX margin XX% $X.X in
including in QX totaling totaled spending expense $XXX,XXX. severance Operating related charges $X and restructuring million of relocation, XXXX, to
from of reduction spending OpEx was charges, XX%. in about projects one-time R&D development these or spending GSK versus million last $X co-funding year, was of $X and OpEx $X.X million Excluding $X.X joint benefited Quell that from million effects of dropped $X.X totaling from largest GSK R&D prior a within million Sales million it The year. last Gross year. $XXX,XXX. QX funding and to advertising prior factor the $X.X was in spending. Quell million $XXX,XXX is of spending was reduced down contributing marketing
sorry, primarily legal. $X.X spending spending higher prior $X.X -- of $X.X million services professional totaled year million. costs, milestones quarter, G&A milestones performance under income total million remaining And Collaboration $X.X now GSK GSK year included ago in million versus $X.X million versus the GSK
million in $X.X QX net of compares in with loss $XXX,XXX net income Our XXXX.
number XX end $X.XX shares outstanding an million. simple as all Our Common Capital converted common remains share free. the and million. equity-only cash convertible the quarter currently be balance preferred Adjusting would million. structure shares X.X was are count at for debt on that basis, of the
Dr. overall Gozani our strategy. now address will